{"name":"Serenity Pharmaceuticals, Inc.","slug":"serenity-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"SER120","genericName":"SER120","slug":"ser120","indication":"Treatment-resistant depression","status":"phase_3"},{"name":"SER120 750 ng","genericName":"SER120 750 ng","slug":"ser120-750-ng","indication":"Major depressive disorder","status":"phase_3"},{"name":"SER120 nasal spray 750 ng/day","genericName":"SER120 nasal spray 750 ng/day","slug":"ser120-nasal-spray-750-ng-day","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"SER120 Nasal Spray 500 ng/day","genericName":"SER120 Nasal Spray 500 ng/day","slug":"ser120-nasal-spray-500-ng-day","indication":"Other","status":"phase_3"},{"name":"SER120 1500 ng","genericName":"SER120 1500 ng","slug":"ser120-1500-ng","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"SER120","genericName":"SER120","slug":"ser120","phase":"phase_3","mechanism":"SER120 is a small molecule that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""},{"name":"SER120 Nasal Spray 500 ng/day","genericName":"SER120 Nasal Spray 500 ng/day","slug":"ser120-nasal-spray-500-ng-day","phase":"phase_3","mechanism":"SER120 is an investigational nasal spray formulation with an unknown mechanism of action.","indications":[],"catalyst":""},{"name":"SER120 1500 ng","genericName":"SER120 1500 ng","slug":"ser120-1500-ng","phase":"phase_3","mechanism":"SER120 is an investigational therapeutic agent in Phase 3 development by Serenity Pharmaceuticals with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"SER120 750 ng","genericName":"SER120 750 ng","slug":"ser120-750-ng","phase":"phase_3","mechanism":"SER120 is a small molecule that targets the serotonin receptor.","indications":["Major depressive disorder"],"catalyst":""},{"name":"SER120 nasal spray 750 ng/day","genericName":"SER120 nasal spray 750 ng/day","slug":"ser120-nasal-spray-750-ng-day","phase":"phase_3","mechanism":"SER120 is a serotonin receptor agonist.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQM0o5clFoWnBEZUNjQlZyemZFZ0s1RWNqdW5ucmNDZEI2R2tDYV95ZXowZHZEblBHOGFLSXp3UXpQZjRRemlHdVhYMkhzbTBWYVI0S1BVNERJeDZGYThSUVV1MjVQb1pOalBFOVVQZWlLUG5hUUY0dEdaeTdMTDZrdzFiakxET1E?oc=5","date":"2025-11-03","type":"pipeline","source":"WTVR.com","summary":"Her county's only drug store closed. Now she lives in a pharmacy desert: 'We have nothing' - WTVR.com","headline":"Her county's only drug store closed. Now she lives in a pharmacy desert: 'We have nothing'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQdWQ0Rl80ZlFpMzVha2EtMmJONW5GWTNMOHFPVmI1Z1RrWUpGMVRiWHZhUDZKczZEVTVXeS11R2RyYmRyWld6WWoxZWZNTUoxb2RiczVodnhFbzZneVRXRkd0dk4wSVhiYjBTVU8tOUFaVThJOV9tS2h5TlExYUZ6TUJ2bmY1dExkdjJEc2FkRnkwUFFPSGdTVQ?oc=5","date":"2025-09-10","type":"trial","source":"seekingalpha.com","summary":"BioXcel Therapeutics, Inc. (BTAI) Discuses on SERENITY At-Home Pivotal Phase 3 Safety - seekingalpha.com","headline":"BioXcel Therapeutics, Inc. (BTAI) Discuses on SERENITY At-Home Pivotal Phase 3 Safety","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPNkZ6WmtlQWcxcXduTHFLNHJiOW4zdUNjYnFBYlpFaW54OXpQUWdFTEZKODNmWkpSWjBIdHRjdWFCbzUtSHpSMlNBSGVkcGVDdi04amR4TEhKSkFNOUNicjhaYUVHbmdnZER0RTRlM2VISTRaSDJxNTRDYVExUXJSUGpZT2lZZVZwam40T1ZRN2NwWjJPTG5ad2RfZnZia2Z0VmR2WkVhN2R4dFp3UklnVzF5YzY1RURqeEp6eHd3?oc=5","date":"2025-08-26","type":"trial","source":"Stock Titan","summary":"Major Clinical Trial Results Coming: BioXcel's BXCL501 Safety Data in Bipolar and Schizophrenia Agitation - Stock Titan","headline":"Major Clinical Trial Results Coming: BioXcel's BXCL501 Safety Data in Bipolar and Schizophrenia Agitation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOa0hlZXpzZjJvWDM5QlFYd3pWOG9KTDhrM01tN2pfQnJFRUZwbmRJdm1oREk4THg0ZkpQM0F6WEdKSGJ0YWNhSVowR0tMbGhRVHBneHE1aFByTG1MN3NXVDlfWEZxbHVYXzF2R2cyaUZ2cHo1UGpYUHQ4M0VvemhtamhoZHhYVWVsVEVKZlY4NmxkTFM4dE5KdDh1MHNuN2pfQmZBVVM5SVRZNHJqNkxNR2hQWmo4STNyNTdBellaY2R3aDhlUWNfczNHWDNuWXBqNUdFOFRmb0ZxQVdyZ0pEci05QWVXR29tYzlPcA?oc=5","date":"2025-05-01","type":"pipeline","source":"prnewswire.com","summary":"IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - prnewswire.com","headline":"IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQb2x3THEzVk5pMkNKU1YzelhWZm5fS21IRHkzendWaXNFYzZmRWlnaFREOC1sV21CaE9GbnhfUGJ2NjFmRGdVQWdDUkxYMERrS0xWN0J1TE83dUdyTkFQcDBYWnhpN1M1LW83RE8xc3hhRDNINGlub3pfb1FQWUNNeFFXMUhTamwtSm91MHpOUkotU0QwQXBrLWtzWS05OURxLXRfZlNMSGJOWVp3Ri1hT0szSnJYR1NxV21v?oc=5","date":"2022-11-21","type":"pipeline","source":"Reuters","summary":"Judge rejects Jones Day sanctions bid in fee fight with pharma client - Reuters","headline":"Judge rejects Jones Day sanctions bid in fee fight with pharma client","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPcThsd0YxdzF6bGdIQVIxaFVMZEU3U1d2amlJdk5GdkVKb2NpSlVNcWlGR1FseW04eW5NazhxelEzbU9fWkNGeFFfcVVUMDVjczZwbUxDb01GRnoyazJTWWdmYm5oRWJEaDE4UEppMk5LSjQ4bTRXZXZJdTAzOFRHazZobjZ2ckk1RkR4U1ZLYVhNT0N5LVRuNXhtRUFLWG1YSVpuY3c5bUJfZEc3eHNKUjhBMlpRbnBFNlFwVi0yMXMxNFIxT0p6VWRNVzFDZUFSNlhmaGlhclROeDZqQVptOWEybTFjMi1FSDlPSWMwVkZvMmhQUTBURGotZWkwOWtOMTZFUVVNYm5FSmkzSzN6R2tTMjBuZw?oc=5","date":"2022-03-07","type":"pipeline","source":"GlobeNewswire","summary":"Acerus Announces Closing of Acquisition of Serenity - GlobeNewswire","headline":"Acerus Announces Closing of Acquisition of Serenity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRTJ3YzZlVjJPVThNVks5U2J2Q3RGSEtMa0dXazVSVkJPNzIzUGVRMzB0ek9lTDF3Q0xYOXdtQmlER2ZNb3pHT3hUV1pIY2RLbWZ1cDJ4UElGWjEzMXhMNVNhaS1RTXFSUE5OY1hkV3M3WjR4YTJjVzVYZUJZdUNwMmtZSEVJcUUyaWxiYWRLVlNxZk12eHRXNFNJSHp4ZVE5S1N5S2kzei03VjRicGJSbUM2Ry1oVG5MNXIydFhSeFR2MWdaWFhkZ0MtQ2M0aXhCYk9idlF2Wl9oYTNlZy1RYXdBZEU1clR2QnE2clBnNkRzbFNkQ09HbHZB?oc=5","date":"2022-02-28","type":"deal","source":"GlobeNewswire","summary":"Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™ - GlobeNewswire","headline":"Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFB3Y2RGVjcwOHVOTkhIbjZtZERNNVRpM00tb0JneVppVldvSko0ejAxZHMwVy1JWjF6TzJfSkdkNG0tQ215X1I4YkVhQmV4TGd0V09BRFZEMjFaSlhqUFhtS1JUa1FYc0VfRnFISTlfRURUQmdYMi1NVQ?oc=5","date":"2021-03-13","type":"regulatory","source":"pharmacytimes.com","summary":"10 FDA Approvals to Know from 2017 - pharmacytimes.com","headline":"10 FDA Approvals to Know from 2017","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOE9fUnJSOXk4VjVsdlZmSWtIemVhd3VraWZnQUF1LTR1Y1Z1U2J0bkVYUzBfRGpKclk4cUxYOWs3czI5T2pDLXhORlk3ZkVqRXNMUk1tQTc4WUsxUWJQS1JKT0hEd1hzaXlvNGwwa1EwY05vNDRDRVRfYVkyNTVuVlJrRkNnYkR6S1pYODZ4ZzhndXVIV21lU0luVzV4aFNRdUNCMXRjQzhYZw?oc=5","date":"2017-03-08","type":"regulatory","source":"BioPharma Dive","summary":"Serenity wins FDA nod on frequent nighttime urination treatment - BioPharma Dive","headline":"Serenity wins FDA nod on frequent nighttime urination treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPUUxkNllqQmRKVHUxLUZ0ZVRIRjBMRkoxd3pYWlEzTVBCX3dMVjZfTk90d19LT0NEOXdILVFNc1IySE1WdjVtaGlYWWdBN1VfNTRybjI3REFKMkF1eEZERkk0Si1CcnlHWkNUSU9Nd0tEX0JOSnJEdVlfYTUtSjBtSjlWc0xodjhJNGdlWXVBbXB1SG10NDR2bTVwNXRRZEVQZDBUYl95S1ZBRnRYM0pNQVNROU1fR1c3eVBmZFFzMFhLbUpTUzJISWRSNUFJQQ?oc=5","date":"2016-10-20","type":"regulatory","source":"prnewswire.com","summary":"FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray) - prnewswire.com","headline":"FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)","sentiment":"positive"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}